Skip to main content
Journal cover image

What do international pharmacoeconomic guidelines say about economic data transferability?

Publication ,  Journal Article
Barbieri, M; Drummond, M; Rutten, F; Cook, J; Glick, HA; Lis, J; Reed, SD; Sculpher, M; Severens, JL ...
Published in: Value Health
December 2010

OBJECTIVES: The objectives of this article were to assess the positions of the various national pharmacoeconomic guidelines on the transferability (or lack of transferability) of clinical and economic data and to review the methods suggested in the guidelines for addressing issues of transferability. METHODS: A review of existing national pharmacoeconomic guidelines was conducted to assess recommendations on the transferability of clinical and economic data, whether there are important differences between countries, and whether common methodologies have been suggested to address key transferability issues. Pharmacoeconomic guidelines were initially identified through the ISPOR Web site. In addition, those national guidelines not included in the ISPOR Web site, but known to us, were also considered. RESULTS: Across 27 sets of guidelines, baseline risk and unit costs were uniformly considered to be of low transferability, while treatment effect was classified as highly transferable. Results were more variable for resource use and utilities, which were considered to have low transferability in 63% and 45% of cases, respectively. There were some differences between older and more recent guidelines in the treatment of transferability issues. CONCLUSIONS: A growing number of jurisdictions are using guidelines for the economic evaluation of pharmaceuticals. The recommendations in existing guidelines regarding the transferability of clinical and economic data are quite diverse. There is a case for standardization in dealing with transferability issues. One important step would be to update guidelines more frequently.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Value Health

DOI

EISSN

1524-4733

Publication Date

December 2010

Volume

13

Issue

8

Start / End Page

1028 / 1037

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Translational Research, Biomedical
  • Humans
  • Health Policy & Services
  • Economics, Pharmaceutical
  • Diffusion of Innovation
  • Cost-Benefit Analysis
  • 4407 Policy and administration
  • 4203 Health services and systems
  • 3801 Applied economics
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Barbieri, M., Drummond, M., Rutten, F., Cook, J., Glick, H. A., Lis, J., … ISPOR Good Research Practices Economic Data Transferability Task Force, . (2010). What do international pharmacoeconomic guidelines say about economic data transferability? Value Health, 13(8), 1028–1037. https://doi.org/10.1111/j.1524-4733.2010.00771.x
Barbieri, Marco, Michael Drummond, Frans Rutten, John Cook, Henry A. Glick, Joanna Lis, Shelby D. Reed, Mark Sculpher, Johan L. Severens, and Johan L. ISPOR Good Research Practices Economic Data Transferability Task Force. “What do international pharmacoeconomic guidelines say about economic data transferability?Value Health 13, no. 8 (December 2010): 1028–37. https://doi.org/10.1111/j.1524-4733.2010.00771.x.
Barbieri M, Drummond M, Rutten F, Cook J, Glick HA, Lis J, et al. What do international pharmacoeconomic guidelines say about economic data transferability? Value Health. 2010 Dec;13(8):1028–37.
Barbieri, Marco, et al. “What do international pharmacoeconomic guidelines say about economic data transferability?Value Health, vol. 13, no. 8, Dec. 2010, pp. 1028–37. Pubmed, doi:10.1111/j.1524-4733.2010.00771.x.
Barbieri M, Drummond M, Rutten F, Cook J, Glick HA, Lis J, Reed SD, Sculpher M, Severens JL, ISPOR Good Research Practices Economic Data Transferability Task Force. What do international pharmacoeconomic guidelines say about economic data transferability? Value Health. 2010 Dec;13(8):1028–1037.
Journal cover image

Published In

Value Health

DOI

EISSN

1524-4733

Publication Date

December 2010

Volume

13

Issue

8

Start / End Page

1028 / 1037

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Translational Research, Biomedical
  • Humans
  • Health Policy & Services
  • Economics, Pharmaceutical
  • Diffusion of Innovation
  • Cost-Benefit Analysis
  • 4407 Policy and administration
  • 4203 Health services and systems
  • 3801 Applied economics